Additionally, Citius has secured patents for Mino-Lok® in both the US and Europe that protect the product throughout the year 2036, and will be pursuing a patent for CITI-002.
CTXR~~In August 2018, the Company raised $10 million with the intent to use the capital from the raise towards our Phase 3 clinical Mino-Lok trial for the treatment of catheter related bloodstream infections (CRBSIs), and Phase 2b clinical trial of CITI-002 for the symptomatic treatment of hemorrhoids. More than $23 million has now been invested into the Company privately by
News 
Market Data 
Discover 
